STENOCARE A / S
NASDAQ FIRST GROWTH MARKET IN THE NORTH, DENMARK
TICKER: STENO
STENOCARE A / S (“STENOCARE”) announces that it has received approval from the Danish Medicines Agency to sell a new medicinal cannabis oil product to Danish patients. With this, STENOCARE is once again the only supplier of medicinal cannabis oil products under the Danish Pilot Program.
STENOCARE is a provider of prescription cannabis products for the treatment of patients. The company has experience in delivering prescription products to patients in Denmark and Sweden, and is now re-entering the Danish market with medicinal cannabis oil products. The source is AgMEDICA Bioscience of Canada.
The product is called “THC Olie STENOCARE” and contains 30 mg / mL of THC. The new product has been examined by the Danish Medicines Agency for compliance with the Danish pilot program and its strict quality standards. After a very thorough process, the product has now been accepted into the Danish program.
The new STENOCARE product becomes the first and only oil product available to patients under the Program. The new product is expected to be available to patients during the first quarter of 2022 pending international import and export certificates. STENOCARE is working with the Danish Medicines Agency to have two more approved products for the Pilot Program, and the products are a CBD oil and a mixed THC-CBD oil.
Thomas Skovlund Schnegelsberg, CEO of STENOCARE comments:
“This announcement marks an important milestone for STENOCARE and our regulatory work with the Danish Medicines Agency. In 2018, we were the first and only ones to have accepted medical cannabis oil products for the Danish Pilot Program. new approval shows that patience and perseverance pay off and we are happy and honored to be the first and only supplier of petroleum products for Danish patients under the pilot program. ”
For more information on STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 Email: presse@stenocare.com
This information is information that STENOCARE A / S is required to publish in accordance with the EU Market Abuse Regulation. The previous contact provided the information for publication on January 7, 2022.
STENOCARE Certified Advisor is Keswick Global AG, Phone: +43 1 740 408045, Email: info@keswickglobal.com
About STENOCARE A / S
STENOCARE A / S was founded in 2017 with the aim of supplying medical cannabis to patients in Denmark and internationally. The company was the first to receive permission from the Danish Medicines Agency to import, distribute, cultivate and produce medicinal cannabis. STENOCARE obtains its products from a number of carefully selected high quality international suppliers and operates a state-of-the-art cultivation facility unique and inland in Denmark, which has multiple levels of redundancy to safeguard quality and uniformity in a pesticide-free production process. .
www.stenocare.com www.stenocare.dk www.stenocare.se
https://news.cision.com/stenocare/r/stenocare-approved-to-supply-danish-patients-with-medical-cannabis-oil-products,c3482425
https://mb.cision.com/Main/17551/3482425/1517950.pdf
(c) Cision 2022. All rights reserved., source Press Releases – English
